Kura Oncology Inc.

01/07/2025 | Press release | Distributed by Public on 01/07/2025 16:43

Initial Statement of Beneficial Ownership (Form 3)

Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Leoni Mollie
2. Date of Event Requiring Statement (Month/Day/Year)
01/02/2025 		3. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [KURA]
(Last) (First) (Middle)
C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400 		4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Medical Officer
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
SAN DIEGO, CA 92130 		6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 46,966(1) D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(Month/Day/Year) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option to purchase common stock (2) 02/09/2030 Common Stock 52,500 $12.22 D
Option to purchase common stock (3) 01/25/2031 Common Stock 22,260 $32.8 D
Option to purchase common stock (4) 01/25/2032 Common Stock 52,500 $14.15 D
Option to purchase common stock (5) 02/15/2033 Common Stock 63,750 $11.99 D
Option to purchase common stock (6) 07/02/2033 Common Stock 40,000 $10.6 D
Option to purchase common stock (7) 01/01/2034 Common Stock 50,000 $15.36 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Leoni Mollie
C/O KURA ONCOLOGY, INC.
12730 HIGH BLUFF DRIVE, SUITE 400
SAN DIEGO, CA 92130 		Chief Medical Officer

Signatures

Teresa Bair, Attorney-in-fact for Mollie Leoni 01/07/2025
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Includes 4,716 shares of common stock and 42,250 shares of common stock that may be issued pursuant to the following restricted stock unit awards (RSUs): (i) 1,781 shares pursuant to a RSU granted on 1/26/21 that will vest on 1/26/25, (ii) 7,500 shares pursuant to a RSU granted on 1/26/22 that will vest in equal installments on 1/26/25 and 1/26/26,(iii) 7,969 shares pursuant to a RSU granted on 2/16/23 that will vest in equal installments on 1/26/25, 1/26/26 and 1/26/27, and (iv) 25,000 shares pursuant to a RSU granted on 1/2/24 that will vest in equal installments on 1/26/25, 1/26/26, 1/26/27 and 1/26/28.
(2) Fully Vested
(3) This option vests in 48 equal monthly installments commencing on the grant date of 1/26/21.
(4) This option vests in 48 equal monthly installments commencing on the grant date of 1/26/22.
(5) This option vests in 48 equal monthly installments commencing on the grant date of 2/16/23.
(6) This option vests in 48 equal monthly installments commencing on the grant date of 7/3/23.
(7) This option vests in 48 equal monthly installments commencing on the grant date of 1/2/24.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.